

## Grifols Egypt begins taking plasma donations

- *Following the Egyptian Drug Authority's approval, donations started in the inaugural 6<sup>th</sup> of October flagship center, on the outskirts of Cairo, the first of 20 plasma collection locations planned for the country as part of the alliance between Grifols and Egypt's National Service Projects Organization*
- *The innovative partnership is developing the world's first integrated plasma-supply platform in which a government and plasma producer combine forces to ensure national and regional self-sufficiency in plasma-derived medicines, a model that can be replicated*
- *Signed in November 2020, the alliance will also build a fractionation plant, a testing laboratory and Grifols Academy to develop local talent in the plasma field*

**Barcelona, Spain, January 18, 2022** - Grifols (MCE:GRF, MCE:GRF.P, NASDAQ:GRFS), one of the world's leading producers of plasma-derived medicines with a more than 110-year track record of contributing to the health and well-being of people around the world, and Egypt's National Service Projects Organization (NSPO) have announced that their inaugural plasma center has begun receiving donations after being licensed by the Egyptian Drug Authority.

The flagship 6<sup>th</sup> of October Center is the first of 20 donation centers that Grifols Egypt for Plasma Derivatives will roll out across the country over the next two years. Local donation regulations, including quality and safety standards, follow those of the U.S. FDA, which for decades has watched over the world's largest and most proficient network of plasma collection centers.

Over time, the plasma collected in Egypt will be converted into hemoderivatives in manufacturing installations in the country, including a plasma fractionation plant, a purification plant and testing and warehousing operations, all up and running by 2025. Until then, all collected plasma, as much as 1 million liters annually, will be processed in Spain before being returned.

Grifols and the NSPO signed their game-changing alliance in November 2020. For the first time anywhere a government entity and a private plasma company are building an integrated plasma-supply platform to ensure adequate national and regional supplies of plasma products.

"The first plasma donations open the beginning of a new era for Egypt, which is now decisively on its way toward plasma self-sufficiency," said Víctor Grifols Deu, co-CEO of Grifols. "Our alliance with the Egyptian government is an innovative and efficient model that will allow plasma therapies to be available on a broad scale."

“Once more, Egyptian healthcare is demonstrating regional leadership as we continue investing resources to enhance the well-being and quality of life of all Egyptians,” said Dr. Magdy Amin, CEO Grifols Egypt.

The 6<sup>th</sup> of October building was officially inaugurated in October. In addition to the flagship donor center, the two-story complex also houses a testing laboratory for screening plasma and a training area belonging to The Grifols Academy, the company’s professional development program for employees, to develop talent locally.

---

## About Grifols Egypt for Plasma Derivatives

Grifols Egypt for Plasma Derivatives is a joint-venture company between Egypt’s National Service Projects Organization and Grifols. The strategic partnership’s combined expertise, technology and resources seeks to strengthen Egypt’s healthcare system through achieving self-sufficiency in plasma-derived medicines while reinforcing Grifols’ international expansion in the Middle East and Africa.

## About Grifols

Grifols is a global healthcare company founded in Barcelona in 1909 committed to improving the health and well-being of people around the world. Its four divisions – Bioscience, Diagnostic, Hospital and Bio Supplies – develop, produce and market innovative solutions and services that are sold in more than 100 countries.

Pioneers in the plasma industry, Grifols operates a growing network of donation centers worldwide. It transforms collected plasma into essential medicines to treat chronic, rare and, at times, life-threatening conditions. As a recognized leader in transfusion medicine, Grifols also offers a comprehensive portfolio of solutions designed to enhance safety from donation to transfusion. In addition, the company supplies tools, information and services that enable hospitals, pharmacies and healthcare professionals to efficiently deliver expert medical care.

Grifols, with more than 24,000 employees in 30 countries and regions, is committed to a sustainable business model that sets the standard for continuous innovation, quality, safety and ethical leadership.

In 2019, Grifols’ economic impact in its core countries of operation was EUR 8.5 billion. The company also generated 148,000 jobs, including indirect and induced.

The company’s class A shares are listed on the Spanish Stock Exchange, where they are part of the Ibex-35 (MCE:GRF). Grifols non-voting class B shares are listed on the Mercado Continuo (MCE:GRF.P) and on the U.S. NASDAQ through ADRs (NASDAQ:GRFS).

For more information, please visit [www.grifols.com](http://www.grifols.com)

## Media contacts:

### Grifols

#### Media Press Office

[media@grifols.com](mailto:media@grifols.com)

Tel. +34 571 00 02

## **Egypt**

### **Egypt's National Service Projects Organization**

Email: [nspo@nspo.com.eg](mailto:nspo@nspo.com.eg)

Tel: +2021816946

## **Investors:**

### **Grifols Investors Relations Department**

[inversores@grifols.com](mailto:inversores@grifols.com) - [investors@grifols.com](mailto:investors@grifols.com)

Tel. +34 93 571 02 21

---

## **LEGAL DISCLAIMER**

The facts and figures contained in this report that do not refer to historical data are “future projections and assumptions”. Words and expressions such as “believe”, “hope”, “anticipate”, “predict”, “expect”, “intend”, “should”, “will seek to achieve”, “it is estimated”, “future” and similar expressions, in so far as they relate to the Grifols group, are used to identify future projections and assumptions. These expressions reflect the assumptions, hypotheses, expectations and predictions of the management team at the time of writing this report, and these are subject to a number of factors that mean that the actual results may be materially different. The future results of the Grifols group could be affected by events relating to its own activities, such as a shortage of supplies of raw materials for the manufacture of its products, the appearance of competitor products on the market, or changes to the regulatory framework of the markets in which it operates, among others. At the date of compiling this report, the Grifols group has adopted the necessary measures to mitigate the potential impact of these events. Grifols, S.A. does not accept any obligation to publicly report, revise or update future projections or assumptions to adapt them to events or circumstances subsequent to the date of writing this report, except where expressly required by the applicable legislation. This document does not constitute an offer or invitation to buy or subscribe shares in accordance with the provisions of the following Spanish legislation: Royal Legislative Decree 4/2015, of 23 October, approving recast text of Securities Market Law; Royal Decree Law 5/2005, of 11 March and/or Royal Decree 1310/2005, of 4 November, and any regulations developing this legislation. In addition, this document does not constitute an offer of purchase, sale or exchange, or a request for an offer of purchase, sale or exchange of securities, or a request for any vote or approval in any other jurisdiction. The information included in this document has not been verified nor reviewed by the external auditors of the Grifols group.